Panagiotis Antiochos1, Pedro Marques-Vidal2, Julien Virzi2, Sabrina Pagano2, Nathalie Satta2, Oliver Hartley2, Fabrizio Montecucco2, François Mach2, Zoltan Kutalik2, Gerard Waeber2, Peter Vollenweider2, Nicolas Vuilleumier2. 1. From the Department of Internal Medicine, University Hospital of Lausanne, Switzerland (P.A., P.M.-V., G.W., P.V.); Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Switzerland (J.V., S.P., N.S., F. Montecucco, N.V.); Department of Human Protein Sciences, Faculty of Medicine, (J.V., S.P., N.S., N.V.), Department of Pathology and Immunology, Faculty of Medicine (O.H.), and Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties (F. Montecucco, F. Mach), University of Geneva, Switzerland; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Italy (F. Montecucco); Institute of Social and Preventive Medicine, University Hospital of Lausanne, Switzerland (Z.K.); and Swiss Institute of Bioinformatics, Lausanne, Switzerland (Z.K.). panagiotis.antiochos@chuv.ch. 2. From the Department of Internal Medicine, University Hospital of Lausanne, Switzerland (P.A., P.M.-V., G.W., P.V.); Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Switzerland (J.V., S.P., N.S., F. Montecucco, N.V.); Department of Human Protein Sciences, Faculty of Medicine, (J.V., S.P., N.S., N.V.), Department of Pathology and Immunology, Faculty of Medicine (O.H.), and Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties (F. Montecucco, F. Mach), University of Geneva, Switzerland; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Italy (F. Montecucco); Institute of Social and Preventive Medicine, University Hospital of Lausanne, Switzerland (Z.K.); and Swiss Institute of Bioinformatics, Lausanne, Switzerland (Z.K.).
Abstract
OBJECTIVE: We aimed to determine whether autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG) predict incident coronary artery disease (CAD), defined as adjudicated incident myocardial infarction, angina, percutaneous coronary revascularization, or bypass grafting, in the general population. We further investigated whether this association is modulated by a functional CD14 receptor single nucleotide polymorphism. APPROACH AND RESULTS: In a prospectively studied, population-based cohort of 5220 subjects (mean age 52.6±10.7 years, 47.4% males), followed over a median period of 5.6 years, subjects positive versus negative for anti-apoA-1 IgG presented a total CAD rate of 3.9% versus 2.8% (P=0.077) and a nonfatal CAD rate of 3.6% versus 2.3% (P=0.018), respectively. After multivariate adjustment for established cardiovascular risk factors, the hazard ratios of anti-apoA-1 IgG for total and nonfatal CAD were: hazard ratio=1.36 (95% confidence interval, 0.94-1.97; P=0.105) and hazard ratio=1.53 (95% confidence interval, 1.03-2.26; P=0.034), respectively. In subjects with available genetic data for the C260T rs2569190 single nucleotide polymorphism in the CD14 receptor gene (n=4247), we observed a significant interaction between anti-apoA-1 IgG and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the highest risk for total and nonfatal CAD in non-TT carriers, whereas being associated with the lowest risk for total and nonfatal CAD in TT homozygotes (P for interaction =0.011 and P for interaction =0.033, respectively). CONCLUSIONS: Anti-apoA-1 IgG are independent predictors of nonfatal incident CAD in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD.
OBJECTIVE: We aimed to determine whether autoantibodies against apoA-1 (apolipoprotein A-1; anti-apoA-1 IgG) predict incident coronary artery disease (CAD), defined as adjudicated incident myocardial infarction, angina, percutaneous coronary revascularization, or bypass grafting, in the general population. We further investigated whether this association is modulated by a functional CD14 receptor single nucleotide polymorphism. APPROACH AND RESULTS: In a prospectively studied, population-based cohort of 5220 subjects (mean age 52.6±10.7 years, 47.4% males), followed over a median period of 5.6 years, subjects positive versus negative for anti-apoA-1 IgG presented a total CAD rate of 3.9% versus 2.8% (P=0.077) and a nonfatal CAD rate of 3.6% versus 2.3% (P=0.018), respectively. After multivariate adjustment for established cardiovascular risk factors, the hazard ratios of anti-apoA-1 IgG for total and nonfatal CAD were: hazard ratio=1.36 (95% confidence interval, 0.94-1.97; P=0.105) and hazard ratio=1.53 (95% confidence interval, 1.03-2.26; P=0.034), respectively. In subjects with available genetic data for the C260T rs2569190 single nucleotide polymorphism in the CD14 receptor gene (n=4247), we observed a significant interaction between anti-apoA-1 IgG and rs2569190 allele status with regards to CAD risk, with anti-apoA-1 IgG conferring the highest risk for total and nonfatal CAD in non-TT carriers, whereas being associated with the lowest risk for total and nonfatal CAD in TT homozygotes (P for interaction =0.011 and P for interaction =0.033, respectively). CONCLUSIONS: Anti-apoA-1 IgG are independent predictors of nonfatal incident CAD in the general population. The strength of this association is dependent on a functional polymorphism of the CD14 receptor gene, a finding suggesting a gene-autoantibody interaction for the development of CAD.
Authors: David Henson; Ayman Samman Tahhan; David Nardo; Arshed Ali Quyyumi; Vincent J Venditto Journal: Arterioscler Thromb Vasc Biol Date: 2019-07-18 Impact factor: 8.311
Authors: Nicolas Vuilleumier; Sabrina Pagano; Christophe Combescure; Baris Gencer; Julien Virzi; Lorenz Räber; David Carballo; Sebastian Carballo; David Nanchen; Nicolas Rodondi; Stephan Windecker; Stanley L Hazen; Zeneng Wang; Xinmin S Li; Arnold von Eckardstein; Christian M Matter; Thomas F Lüscher; Roland Klingenberg; Francois Mach Journal: J Clin Med Date: 2019-07-09 Impact factor: 4.241
Authors: Sabrina Pagano; Alessandra Magenta; Marco D'Agostino; Francesco Martino; Francesco Barillà; Nathalie Satta; Miguel A Frias; Annalisa Ronca; François Mach; Baris Gencer; Elda Favari; Nicolas Vuilleumier Journal: J Clin Med Date: 2019-11-21 Impact factor: 4.241
Authors: Javier Rodríguez-Carrio; Jes S Lindholt; Marina Canyelles; Diego Martínez-López; Mireia Tondo; Luis M Blanco-Colio; Jean-Baptiste Michel; Joan Carles Escolà-Gil; Ana Suárez; José Luis Martín-Ventura Journal: J Clin Med Date: 2019-12-26 Impact factor: 4.241